Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma

@article{GrilloLpez2002ZevalinTF,
  title={Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma},
  author={Antonio J. Grillo-L{\'o}pez},
  journal={Expert Review of Anticancer Therapy},
  year={2002},
  volume={2},
  pages={485 - 493}
}
Conjugated antibodies have been in clinical trials for over 30 years. Immunotoxins, chemotherapy conjugates and radioimmunotherapies have been evaluated. Zevalin™, the first conjugated antibody for the treatment of non-hodgkin's lymphoma (NHL) (and the first radioimmunotherapeutic for cancer) was approved by the US FDA on 19 February 2002 (approval is pending in the EEC). Zevalin (90Yttrium ibritumomab tiuxetan) has been in clinical trials since 1992. Several studies have been conducted… 
Radioimmunotherapy in follicular lymphoma.
Rituximab (Rituxan®/MabThera®): the first decade (1993–2003)
TLDR
Rituximab has been characterized as the most important therapeutic development of the decade and has had an important impact on treatment strategies for lymphoma and other hematologic malignancies.
Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma.
TLDR
Factors that should be considered when assessing whether a patient is a good candidate for treatment with RIT are explored, and aids physicians in the selection of the most appropriate therapy for each patient group.
90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma.
TLDR
Radioimmunotherapy with 90Y-ibritumomab tiuxetan is well tolerated and produces statistically and clinically significant higher overall and complete response rates than rituximab alone.
The Potency of Radiolabelled Monoclonal Antibody Anti-CD20 as A Targeted Therapy for B-cell Non-Hodgkin Lymphoma: A Review
The treatment of B-cell non-Hodgkin lymphoma (NHL) still has the problems, such as a high rate of relapse and refractory case. The use of radioimmunotherapy (RIT) appears to be a treatment modality
Radioimmunotherapy for NHL: Experience of 90Y-Ibritumomab Tiuxetan in Clinical Practice
TLDR
Treating 90Y-ibritumomab tiuxetan as single-agent therapy for relapsed diffuse large B-cell lymphoma patients not eligible for transplantation, and consolidation treatment for low-grade NHL patients after first-line, alkylating agent-based therapy.
The use of 90yttrium-ibritumomab tiuxetan in patients on dialysis: what do we know regarding its pharmacokinetics?
TLDR
A single case of relapsed NHL and ESRD who was treated with Zevalin while on dialysis has the typical myelosuppression pattern expected with radioimmunotherapy (RIT) and no unexpected non-hematological toxicities.
Ibritumomab tiuxetan for non-Hodgkin’s lymphoma
TLDR
Radioimmunotherapy has great promise and the safe incorporation of 90Y ibritumomab tiuxetan into treatment will hopefully result in improved survival for patients with NHL.
Recommendations for the use of Yttrium‐90 ibritumomab tiuxetan in malignant lymphoma
TLDR
Current recommendations for the use of 90Y‐ibritumomab tiuxetan in patients with malignant lymphoma are focused on, future perspectives are outlined, and practical recommendations for patient management are provided.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 47 REFERENCES
Monoclonal antibodies: a new era in the treatment of non-Hodgkin's lymphoma.
TLDR
Rituxan is effective in patients with low-grade or follicular, relapsed or refractory non-Hodgkin's lymphoma and is also active in intermediate-grade NHL where a large randomized study, in combination with CHOP chemotherapy, has shown a statistically significant increase in complete response (CR) rate.
Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody.
TLDR
The chimeric monoclonal antibody Rituximab has now been approved by the United States Food and Drug Administration as a treatment for patients with relapsed or refractory, low-grade or follicular, B-cell NHL.
Radioimmunotherapy of B-cell NHL.
TLDR
The response rates for RIT have been higher than (sometimes nearly double) those for unlabeled antibody therapy, and the toxicity from a single course of RIT is very favorable compared to chemotherapy.
Antibody-targeted immunotherapy for treatment of malignancy.
TLDR
Despite testing since the mid-1900s, only in the past three years have some monoclonal antibodies provided sufficient efficacy and safety data to support regulatory approval as cancer therapy, and the full potential of immunotherapy still lies ahead.
Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
TLDR
Rituximab, the first monoclonal antibody approved for the treatment of cancer, is safe and effective in treating patients with relapsed or refractory, CD-20 positive, B-cell, low-grade or follicular non-Hodgkin's lymphoma.
AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients
TLDR
The impact of antiCD20 antibodies, particularly rituximab and ibritumomab, is evident in the way treatment strategies and outcomes have changed for the lymphoma patient.
Antibody-targeted immunotherapy for treatment of non-Hodgkin's lymphoma.
TLDR
Ibritumomab, the parent murine antibody of Rituximab, is conjugated to the radioisotope 90Y to create 90Y Ibritumoab tiuxetan, (90Y Zevalin, IDEC-Y2B8).
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.
TLDR
Data on the use of radiolabeled monoclonal antibodies directed against the CD20 antigen on malignant B cells is reviewed and the questions of long-term toxicity (late effects) are addressed.
Monoclonal antibody therapy of B cell lymphoma
TLDR
Research geared towards understanding mAb mechanisms of action and the rational design of the next generation of mAb-based regimens will allow to take full advantage of this exciting new mode of therapy.
...
1
2
3
4
5
...